Cadila Healthcare gains on USFDA nod for memory loss drug

NEW DELHI: Shares of Cadile Healthcare rose over 1 per cent on Tuesday after it received the USFDA approval to market Rivastigmine Transdermal System, marking its first approval for a transdermal product in the US.

The scrip hovered at Rs 327.30, up 1.27 per cent at 12:52 pm while the benchmark BSE Sensex was up 0.41 per cent at 36,210.66.

"Rivastigmine Transdermal System is indicated for the treatment of dementia (memory loss) associated with Alzheimer’s and Parkinson’s diseases. It will be manufactured at Zydus Technologies Ltd, the group’s manufacturing facility dedicated to the production oftransdermals, located at SEZ, Ahmedabad," the company said in a BSE filing.


The group also received the final approval for Rosuvastatin Tablets USP (US RLD —Crestor) in the strengths of 5 mg, 10 mg, 20 mg, and 40 mg. It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad.

The group now has 252 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04.

Meanwhile, the shares of Cadile Healthcare opened at Rs 321 on BSE against its previous closing of Rs 323.20.